Rosewind CORP (RSWN)

Sorry, no known transcripts

Recent filings

Submission of Matters to a Vote of Security - May 20, 2022

Rosewind: Aytu Biopharma Reports Third Quarter 2022 Financial Results And Outlines Key Strategic Priorities - May 16, 2022

Rosewind: Aytu Biopharma Announces Positive Preclinical Data In Ventilator-Associated Pneumonia With Its Novel, Proprietary Healightâ„¢ Delivery Technology - April 25, 2022

Rosewind: Aytu Biopharma Announces Fast Track Designation Granted To - April 19, 2022

Additional definitive proxy soliciting materials and Rule 14(a)(12) material - April 7, 2022

Rosewind CORP releases salary data. CEO sees compensation rise 291% - April 7, 2022

Rosewind: Aytu Biopharma Announces Fda Orange Book Listing Of Newly Issued Patent For Cotempla XR-ODT - March 23, 2022

Rosewind CORP just filed a prospectus, suggesting it plans to soon issue some securities - March 3, 2022

Rosewind: Aytu Biopharma Announces Ar101 Granted Orphan Designation In Europe For The - March 2, 2022

Annual report [Section 13 and 15(d), not S-K Item 405] - Feb. 22, 2022

Rosewind: Aytu Biopharma Announces Business And Pipeline Progress And Reports Second Quarter 2022 Financial Results - Feb. 14, 2022

Rosewind CORP Just Filed Its Quarterly Report: 16. Net Loss per Com... - Feb. 14, 2022

Timothy P. Lynch just issued a filing suggesting it has sold all of its Rosewind CORP - Feb. 11, 2022

Rosewind: Aytu Biopharma Completes $15 Million Debt Refinancing - Jan. 31, 2022

Rosewind CORP's Chief Financial Officer just declared 0 ownership of the company. - Jan. 19, 2022

Rosewind CORP's Chief Financial Officer just picked up 100,000 shares - Jan. 19, 2022

Rosewind: Aytu Biopharma Appoints Mark Oki As Chief Financial Officer - Jan. 4, 2022

Rosewind: Aytu Biopharma Announces Fda Clearance Of Investigational New Drug (Ind) Application For Ar101/Enzastaurin In Vascular Ehlers-Danlos Syndrome - Dec. 13, 2021

Departure of Directors or Certain - Dec. 13, 2021

Rosewind CORP Just Filed Its Quarterly Report: 15. Net Loss per Com... - Nov. 15, 2021

Rosewind: Aytu Biopharma Reports First Quarter 2022 Financial Results - Nov. 15, 2021

Notice of Effectiveness - Oct. 7, 2021

Delaying amendment - Sept. 29, 2021

Rosewind CORP Just Filed Its Annual Report: Net Loss Per Common ... - Sept. 28, 2021

Registration statement under Securities Act of 1933 - Sept. 28, 2021

Rosewind: Aytu Biopharma Reports Fourth Quarter And Full-Year - Sept. 27, 2021

Steven Boyd just provided an update on activist position in Rosewind CORP - Sept. 1, 2021

Steven Boyd just provided an update on activist position in Rosewind CORP - Aug. 31, 2021

Departure of Directors or Certain - Aug. 30, 2021

Entry into a Material Definitive - July 2, 2021

Entry into a Material Definitive - June 7, 2021

Rosewind CORP just filed a prospectus, suggesting it plans to soon issue some securities - June 7, 2021

Prospectus [Rule 424(b)(3)] - June 7, 2021

Rosewind: Neos Therapeutics, Inc. And Subsidiaries - May 21, 2021

Current report, items 5.07 and 9.01 - May 21, 2021

Rosewind: Form, Schedule Or Registration Statement No Filing Party: Date Filed: AYTU BIOPHARMA, INC. - May 20, 2021

Current report, item 1.02 - May 20, 2021

Additional definitive proxy soliciting materials and Rule 14(a)(12) material - May 20, 2021

Rosewind: Aytu Biopharma Reports Fiscal Third Quarter 2021 Financial Results And Recent Business Highlights Closed - May 17, 2021

Rosewind CORP director just picked up 9,044 shares - May 10, 2021

Current report, items 1.01, 2.01, and 5.02 - April 16, 2021

Rosewind CORP's Chief Executive Officer just picked up 800,000 shares - April 16, 2021

Rosewind CORP director just picked up 187,804 shares - April 16, 2021

Rosewind CORP director just picked up 187,804 shares - April 16, 2021

Rosewind CORP director just picked up 187,804 shares - April 16, 2021

Statement of changes in beneficial ownership of securities - April 16, 2021

Rosewind CORP director just picked up 6,500 shares - April 12, 2021

Statement of changes in beneficial ownership of securities - April 12, 2021

Rosewind CORP's Chief Financial Officer just declared owning 13,734 shares of Rosewind CORP - April 5, 2021

Current report, items 1.01, 1.02, 5.02, and 9.01 - April 5, 2021

Rosewind CORP's Chief Financial Officer just picked up 55,000 shares - April 5, 2021

Rosewind CORP director just declared owning 24,901 shares of Rosewind CORP - March 31, 2021

Israel A. Englander just provided an update on share ownership of Rosewind CORP - March 26, 2021

Rosewind CORP director just declared owning 2,552 shares of Rosewind CORP - March 26, 2021

On March - March 23, 2021

Prospectuses and communications, business combinations - March 22, 2021

Rosewind: Press Release Dated March 22, 2021 - March 22, 2021

Timothy P. Lynch just provided an update on share ownership of Rosewind CORP - Feb. 12, 2021

Rosewind: Aytu Bioscience Announces Record Fiscal Q2 2021 Net Revenue Of $15.1 Million, An Increase Of 3 - Feb. 11, 2021

Quarterly report [Sections 13 or 15(d)] - Feb. 11, 2021

Prospectuses and communications, business combinations - Feb. 10, 2021

Notice of Effectiveness - Feb. 9, 2021

Rosewind CORP just filed a prospectus, suggesting it plans to soon issue some securities - Feb. 9, 2021

Registration of securities, business combinations - Feb. 9, 2021

Registration of securities, business combinations - Jan. 27, 2021

On January - Jan. 25, 2021

Prospectuses and communications, business combinations - Jan. 6, 2021

Sabby Volatility Warrant Master Fund, Ltd. just provided an update on share ownership of Rosewind CORP - Jan. 5, 2021

Steven Boyd just provided an update on activist position in Rosewind CORP - Dec. 21, 2020

Current report, item 8.01 - Dec. 16, 2020

Rosewind: Investor Presentation, Dated December 15, 2020 - Dec. 15, 2020

Prospectuses and communications, business combinations - Dec. 15, 2020

Rosewind CORP director just picked up 1,333,334 shares - Dec. 15, 2020

Rosewind: Press Release Dated December 10, 2020 - Dec. 14, 2020

Prospectuses and communications, business combinations - Dec. 14, 2020

Rosewind CORP just filed a prospectus, suggesting it plans to soon issue some securities - Dec. 14, 2020

Rosewind CORP just filed a prospectus, suggesting it plans to soon issue some securities - Dec. 11, 2020

Current report, items 7.01 and 9.01 - Dec. 10, 2020

Rosewind: Audited Financial Statements Of Neos Therapeutics, Inc. As Of And For The Years Ended December 31, 2019 And December 31, 2018 - Dec. 10, 2020

Prospectuses and communications, business combinations - Dec. 10, 2020

Rosewind CORP just filed a prospectus, suggesting it plans to soon issue some securities - Dec. 10, 2020

Entry into a Material Definitive - Dec. 10, 2020

Prospectuses and communications, business combinations - Dec. 10, 2020

Prospectuses and communications, business combinations - Dec. 10, 2020

Rosewind CORP just filed a prospectus, suggesting it plans to soon issue some securities - Dec. 10, 2020

Rosewind: Press Release Issued By Aytu Bioscience, Inc., Dated December 10, 2020 Exhibit 99.1 - Dec. 10, 2020

Prospectuses and communications, business combinations - Dec. 10, 2020

As a result of the reverse - Dec. 8, 2020

Sorry, no schedule available for this company

 


Feedback